A PHP Error was encountered

Severity: Warning

Message: fopen(/var/cpanel/php/sessions/ea-php72/ci_sessiona0c0fa2bef3b4d89698e64107555ef7b060babfb): failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 176

Backtrace:

File: /home/rejovjcx/mraccuracyreports.com/application/controllers/Reportdetails.php
Line: 10
Function: library

File: /home/rejovjcx/mraccuracyreports.com/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/cpanel/php/sessions/ea-php72)

Filename: Session/Session.php

Line Number: 143

Backtrace:

File: /home/rejovjcx/mraccuracyreports.com/application/controllers/Reportdetails.php
Line: 10
Function: library

File: /home/rejovjcx/mraccuracyreports.com/index.php
Line: 315
Function: require_once

Global and United States Refractory Multiple Myeloma Market Report & Forecast 2024-2034

img

Global and United States Refractory Multiple Myeloma Market Report & Forecast 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global and United States Refractory Multiple Myeloma Market Report & Forecast 2024-2034

Market Analysis and InsightsGlobal and United States Refractory Multiple Myeloma Market
This report focuses on global and United States Refractory Multiple Myeloma market, also covers the segmentation data of other regions in regional level and county level.
The global Refractory Multiple Myeloma revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2033 with a CAGR of % during the review period (2023-2033).
In United States the Refractory Multiple Myeloma revenue is expected to grow from US$ million in 2022 to US$ million by 2033, at a CAGR of % during the forecast period 2023-2033.
The global key players of Refractory Multiple Myeloma include Bristol Myers Squibb, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Janssen Global Services, LLC, Gilead Sciences, Inc., Fresenius Kabi, GSK plc., Novartis AG and Takeda Pharmaceutical Company Limited, etc. The global five biggest players hold a share of % in 2022.
Global Refractory Multiple Myeloma Scope and Market Size
Refractory Multiple Myeloma market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Refractory Multiple Myeloma market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2033.
For United States market, this report focuses on the Refractory Multiple Myeloma market size by players, by Type and by Application, for the period 2018-2033. The key players include the global and local players, which play important roles in United States.



By Company


Bristol Myers Squibb
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Janssen Global Services, LLC
Gilead Sciences, Inc.
Fresenius Kabi
GSK plc.
Novartis AG
Takeda Pharmaceutical Company Limited
Genentech, Inc.
Segment by Type
Proteosome Inhibitor
Immunomodulators
Anti-CD38 Monoclonal Antibody
Others

Segment by Application


Hospital
Specialty Clinic
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Refractory Multiple Myeloma definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Refractory Multiple Myeloma companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Refractory Multiple Myeloma in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Refractory Multiple Myeloma revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions

Table of Content

1 Study Coverage
1.1 Refractory Multiple Myeloma Product Introduction
1.2 Global Refractory Multiple Myeloma Outlook 2018 VS 2022 VS 2033
1.2.1 Global Refractory Multiple Myeloma Market Size for the Year 2018-2033
1.2.2 United States Refractory Multiple Myeloma Market Size for the Year 2018-2033
1.3 Refractory Multiple Myeloma Market Size, United States VS Global, 2018 VS 2022 VS 2033
1.3.1 The Market Share of United States Refractory Multiple Myeloma in Global, 2018 VS 2022 VS 2033
1.3.2 The Growth Rate of Refractory Multiple Myeloma Market Size, United States VS Global, 2018 VS 2022 VS 2033
1.4 Refractory Multiple Myeloma Market Dynamics
1.4.1 Refractory Multiple Myeloma Industry Trends
1.4.2 Refractory Multiple Myeloma Market Drivers
1.4.3 Refractory Multiple Myeloma Market Challenges
1.4.4 Refractory Multiple Myeloma Market Restraints
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Refractory Multiple Myeloma by Type
2.1 Refractory Multiple Myeloma Market Segment by Type
2.1.1 Proteosome Inhibitor
2.1.2 Immunomodulators
2.1.3 Anti-CD38 Monoclonal Antibody
2.1.4 Others
2.2 Global Refractory Multiple Myeloma Market Size by Type (2018, 2022 & 2033)
2.3 Global Refractory Multiple Myeloma Market Size by Type (2018-2033)
2.4 United States Refractory Multiple Myeloma Market Size by Type (2018, 2022 & 2033)
2.5 United States Refractory Multiple Myeloma Market Size by Type (2018-2033)
3 Refractory Multiple Myeloma by Application
3.1 Refractory Multiple Myeloma Market Segment by Application
3.1.1 Hospital
3.1.2 Specialty Clinic
3.1.3 Others
3.2 Global Refractory Multiple Myeloma Market Size by Application (2018, 2022 & 2033)
3.3 Global Refractory Multiple Myeloma Market Size by Application (2018-2033)
3.4 United States Refractory Multiple Myeloma Market Size by Application (2018, 2022 & 2033)
3.5 United States Refractory Multiple Myeloma Market Size by Application (2018-2033)
4 Global Refractory Multiple Myeloma Competitor Landscape by Company
4.1 Global Refractory Multiple Myeloma Market Size by Company
4.1.1 Global Key Companies of Refractory Multiple Myeloma, Ranked by Revenue (2022)
4.1.2 Global Refractory Multiple Myeloma Revenue by Player (2018-2023)
4.2 Global Refractory Multiple Myeloma Concentration Ratio (CR)
4.2.1 Refractory Multiple Myeloma Market Concentration Ratio (CR) (2018-2023)
4.2.2 Global Top 5 and Top 10 Largest Companies of Refractory Multiple Myeloma in 2022
4.2.3 Global Refractory Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Players of Refractory Multiple Myeloma Head office and Area Served
4.4 Global Key Players of Refractory Multiple Myeloma, Product and Application
4.5 Global Key Players of Refractory Multiple Myeloma, Date of Enter into This Industry
4.6 Companies Mergers & Acquisitions, Expansion Plans
4.7 United States Refractory Multiple Myeloma Market Size by Company
4.7.1 Key Players of Refractory Multiple Myeloma in United States, Ranked by Revenue (2022)
4.7.2 United States Refractory Multiple Myeloma Revenue by Players (2021, 2022 & 2023)
5 Global Refractory Multiple Myeloma Market Size by Region
5.1 Global Refractory Multiple Myeloma Market Size by Region: 2018 VS 2022 VS 2033
5.2 Global Refractory Multiple Myeloma Market Size by Region (2018-2033)
5.2.1 Global Refractory Multiple Myeloma Market Size by Region: 2018-2023
5.2.2 Global Refractory Multiple Myeloma Market Size by Region (2024-2033)
6 Americas
6.1 Americas Refractory Multiple Myeloma Market Size YoY Growth 2018-2033
6.2 Americas Refractory Multiple Myeloma Market Size by Type
6.2.1 Americas Refractory Multiple Myeloma Market Size by Type (2018-2023)
6.2.2 Americas Refractory Multiple Myeloma Market Size by Type (2024-2033)
6.2.3 Americas Refractory Multiple Myeloma Market Share by Type (2018-2033)
6.3 Americas Refractory Multiple Myeloma Market Size by Application
6.3.1 Americas Refractory Multiple Myeloma Market Size by Application (2018-2023)
6.3.2 Americas Refractory Multiple Myeloma Market Size by Application (2024-2033)
6.3.3 Americas Refractory Multiple Myeloma Market Share by Application (2018-2033)
6.4 Americas Refractory Multiple Myeloma Market Facts & Figures by Country (2018, 2022 & 2033)
6.4.1 United States
6.4.2 Canada
6.4.3 Mexico
6.4.4 Brazil
7 EMEA
7.1 EMEA Refractory Multiple Myeloma Market Size YoY Growth 2018-2033
7.2 EMEA Refractory Multiple Myeloma Market Size by Type
7.2.1 EMEA Refractory Multiple Myeloma Market Size by Type (2018-2023)
7.2.2 EMEA Refractory Multiple Myeloma Market Size by Type (2024-2033)
7.2.3 EMEA Refractory Multiple Myeloma Market Share by Type (2018-2033)
7.3 EMEA Refractory Multiple Myeloma Market Size by Application
7.3.1 EMEA Refractory Multiple Myeloma Market Size by Application (2018-2023)
7.3.2 EMEA Refractory Multiple Myeloma Market Size by Application (2024-2033)
7.3.3 EMEA Refractory Multiple Myeloma Market Share by Application (2018-2033)
7.4 EMEA Refractory Multiple Myeloma Market Facts & Figures by Country (2018, 2022 & 2033)
7.4.1 Europe
7.4.2 Middle East
7.4.3 Africa
8 China
8.1 China Refractory Multiple Myeloma Market Size YoY Growth 2018-2033
8.2 China Refractory Multiple Myeloma Market Size by Type
8.2.1 China Refractory Multiple Myeloma Market Size by Type (2018-2023)
8.2.2 China Refractory Multiple Myeloma Market Size by Type (2024-2033)
8.2.3 China Refractory Multiple Myeloma Market Share by Type (2018-2033)
8.3 China Refractory Multiple Myeloma Market Size by Application
8.3.1 China Refractory Multiple Myeloma Market Size by Application (2018-2023)
8.3.2 China Refractory Multiple Myeloma Market Size by Application (2024-2033)
8.3.3 China Refractory Multiple Myeloma Market Share by Application (2018-2033)
9 APAC (excluding China)
9.1 APAC Refractory Multiple Myeloma Market Size YoY Growth 2018-2033
9.2 APAC Refractory Multiple Myeloma Market Size by Type
9.2.1 APAC Refractory Multiple Myeloma Market Size by Type (2018-2023)
9.2.2 APAC Refractory Multiple Myeloma Market Size by Type (2024-2033)
9.2.3 APAC Refractory Multiple Myeloma Market Share by Type (2018-2033)
9.3 APAC Refractory Multiple Myeloma Market Size by Application
9.3.1 APAC Refractory Multiple Myeloma Market Size by Application (2018-2023)
9.3.2 APAC Refractory Multiple Myeloma Market Size by Application (2024-2033)
9.3.3 APAC Refractory Multiple Myeloma Market Share by Application (2018-2033)
9.4 APAC Refractory Multiple Myeloma Market Facts & Figures by Country (2018, 2022 & 2033)
9.4.1 Japan
9.4.2 South Korea
9.4.3 China Taiwan
9.4.4 Southeast Asia
9.4.5 India
10 Key Players Profiles
10.1 Bristol Myers Squibb
10.1.1 Bristol Myers Squibb Company Details
10.1.2 Bristol Myers Squibb Business Overview
10.1.3 Bristol Myers Squibb Refractory Multiple Myeloma Introduction
10.1.4 Bristol Myers Squibb Revenue in Refractory Multiple Myeloma Business (2018-2023)
10.1.5 Bristol Myers Squibb Recent Development
10.2 Teva Pharmaceutical Industries Ltd.
10.2.1 Teva Pharmaceutical Industries Ltd. Company Details
10.2.2 Teva Pharmaceutical Industries Ltd. Business Overview
10.2.3 Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Introduction
10.2.4 Teva Pharmaceutical Industries Ltd. Revenue in Refractory Multiple Myeloma Business (2018-2023)
10.2.5 Teva Pharmaceutical Industries Ltd. Recent Development
10.3 Pfizer Inc.
10.3.1 Pfizer Inc. Company Details
10.3.2 Pfizer Inc. Business Overview
10.3.3 Pfizer Inc. Refractory Multiple Myeloma Introduction
10.3.4 Pfizer Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023)
10.3.5 Pfizer Inc. Recent Development
10.4 Janssen Global Services, LLC
10.4.1 Janssen Global Services, LLC Company Details
10.4.2 Janssen Global Services, LLC Business Overview
10.4.3 Janssen Global Services, LLC Refractory Multiple Myeloma Introduction
10.4.4 Janssen Global Services, LLC Revenue in Refractory Multiple Myeloma Business (2018-2023)
10.4.5 Janssen Global Services, LLC Recent Development
10.5 Gilead Sciences, Inc.
10.5.1 Gilead Sciences, Inc. Company Details
10.5.2 Gilead Sciences, Inc. Business Overview
10.5.3 Gilead Sciences, Inc. Refractory Multiple Myeloma Introduction
10.5.4 Gilead Sciences, Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023)
10.5.5 Gilead Sciences, Inc. Recent Development
10.6 Fresenius Kabi
10.6.1 Fresenius Kabi Company Details
10.6.2 Fresenius Kabi Business Overview
10.6.3 Fresenius Kabi Refractory Multiple Myeloma Introduction
10.6.4 Fresenius Kabi Revenue in Refractory Multiple Myeloma Business (2018-2023)
10.6.5 Fresenius Kabi Recent Development
10.7 GSK plc.
10.7.1 GSK plc. Company Details
10.7.2 GSK plc. Business Overview
10.7.3 GSK plc. Refractory Multiple Myeloma Introduction
10.7.4 GSK plc. Revenue in Refractory Multiple Myeloma Business (2018-2023)
10.7.5 GSK plc. Recent Development
10.8 Novartis AG
10.8.1 Novartis AG Company Details
10.8.2 Novartis AG Business Overview
10.8.3 Novartis AG Refractory Multiple Myeloma Introduction
10.8.4 Novartis AG Revenue in Refractory Multiple Myeloma Business (2018-2023)
10.8.5 Novartis AG Recent Development
10.9 Takeda Pharmaceutical Company Limited
10.9.1 Takeda Pharmaceutical Company Limited Company Details
10.9.2 Takeda Pharmaceutical Company Limited Business Overview
10.9.3 Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Introduction
10.9.4 Takeda Pharmaceutical Company Limited Revenue in Refractory Multiple Myeloma Business (2018-2023)
10.9.5 Takeda Pharmaceutical Company Limited Recent Development
10.10 Genentech, Inc.
10.10.1 Genentech, Inc. Company Details
10.10.2 Genentech, Inc. Business Overview
10.10.3 Genentech, Inc. Refractory Multiple Myeloma Introduction
10.10.4 Genentech, Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023)
10.10.5 Genentech, Inc. Recent Development
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.2 Data Source
12.2 Disclaimer
12.3 Author Details

List of Figure

List of Tables
Table 1. Refractory Multiple Myeloma Market Size United States VS Global, CAGR (2018 VS 2022 VS 2033)
Table 2. Refractory Multiple Myeloma Market Trends
Table 3. Refractory Multiple Myeloma Market Drivers
Table 4. Refractory Multiple Myeloma Market Challenges
Table 5. Refractory Multiple Myeloma Market Restraints
Table 6. Global Refractory Multiple Myeloma Market Size by Type: 2018 VS 2022 VS 2033 (US$ Million)
Table 7. United States Refractory Multiple Myeloma Market Size by Type: 2018 VS 2022 VS 2033 (US$ Million)
Table 8. Global Refractory Multiple Myeloma Market Size by Application: 2018 VS 2022 VS 2033 (US$ Million)
Table 9. United States Refractory Multiple Myeloma Market Size by Application: 2018 VS 2022 VS 2033 (US$ Million)
Table 10. Global Key Companies of Refractory Multiple Myeloma, Ranked by Revenue (2022) & (US$ Million)
Table 11. Global Refractory Multiple Myeloma Revenue by Player, (US$ Million), 2018-2023
Table 12. Global Refractory Multiple Myeloma Revenue Share by Player, 2018-2023
Table 13. Global Refractory Multiple Myeloma Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Refractory Multiple Myeloma by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Refractory Multiple Myeloma as of 2022)
Table 15. Global Key Players of Refractory Multiple Myeloma, Headquarters and Area Served
Table 16. Global Key Players of Refractory Multiple Myeloma, Product and Application
Table 17. Global Key Players of Refractory Multiple Myeloma, Date of Enter into This Industry
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Key Players of Refractory Multiple Myeloma in United States, Ranked by Revenue (2022) & (US$ Million)
Table 20. United States Refractory Multiple Myeloma Revenue by Players, (US$ Million), 2021, 2022 & 2023
Table 21. United States Refractory Multiple Myeloma Revenue Share by Players, 2021, 2022 & 2023
Table 22. Global Refractory Multiple Myeloma Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 23. Global Refractory Multiple Myeloma Market Size by Region (2018-2023) & (US$ Million)
Table 24. Global Refractory Multiple Myeloma Market Size Forecast by Region (2024-2033) & (US$ Million)
Table 25. Americas Refractory Multiple Myeloma Market Size by Type (2018-2023) & (US$ Million)
Table 26. Americas Refractory Multiple Myeloma Market Size by Type (2024-2033) & (US$ Million)
Table 27. Americas Refractory Multiple Myeloma Market Size by Application (2018-2023) & (US$ Million)
Table 28. Americas Refractory Multiple Myeloma Market Size by Application (2024-2033) & (US$ Million)
Table 29. Americas Refractory Multiple Myeloma Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 30. Americas Refractory Multiple Myeloma Market Size by Country (2018-2023) & (US$ Million)
Table 31. Americas Refractory Multiple Myeloma Market Size by Country (2024-2033) & (US$ Million)
Table 32. EMEA Refractory Multiple Myeloma Market Size by Type (2018-2023) & (US$ Million)
Table 33. EMEA Refractory Multiple Myeloma Market Size by Type (2024-2033) & (US$ Million)
Table 34. EMEA Refractory Multiple Myeloma Market Size by Application (2018-2023) & (US$ Million)
Table 35. EMEA Refractory Multiple Myeloma Market Size by Application (2024-2033) & (US$ Million)
Table 36. EMEA Refractory Multiple Myeloma Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. EMEA Refractory Multiple Myeloma Market Size by Country (2018-2023) & (US$ Million)
Table 38. EMEA Refractory Multiple Myeloma Market Size by Country (2024-2033) & (US$ Million)
Table 39. China Refractory Multiple Myeloma Market Size by Type (2018-2023) & (US$ Million)
Table 40. China Refractory Multiple Myeloma Market Size by Type (2024-2033) & (US$ Million)
Table 41. China Refractory Multiple Myeloma Market Size by Application (2018-2023) & (US$ Million)
Table 42. China Refractory Multiple Myeloma Market Size by Application (2024-2033) & (US$ Million)
Table 43. China Refractory Multiple Myeloma Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. APAC Refractory Multiple Myeloma Market Size by Type (2018-2023) & (US$ Million)
Table 45. APAC Refractory Multiple Myeloma Market Size by Type (2024-2033) & (US$ Million)
Table 46. APAC Refractory Multiple Myeloma Market Size by Application (2018-2023) & (US$ Million)
Table 47. APAC Refractory Multiple Myeloma Market Size by Application (2024-2033) & (US$ Million)
Table 48. APAC Refractory Multiple Myeloma Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 49. APAC Refractory Multiple Myeloma Market Size by Region (2018-2023) & (US$ Million)
Table 50. APAC Refractory Multiple Myeloma Market Size by Region (2024-2033) & (US$ Million)
Table 51. Bristol Myers Squibb Company Details
Table 52. Bristol Myers Squibb Business Overview
Table 53. Bristol Myers Squibb Refractory Multiple Myeloma Product
Table 54. Bristol Myers Squibb Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 55. Bristol Myers Squibb Recent Development
Table 56. Teva Pharmaceutical Industries Ltd. Company Details
Table 57. Teva Pharmaceutical Industries Ltd. Business Overview
Table 58. Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Product
Table 59. Teva Pharmaceutical Industries Ltd. Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 60. Teva Pharmaceutical Industries Ltd. Recent Development
Table 61. Pfizer Inc. Company Details
Table 62. Pfizer Inc. Business Overview
Table 63. Pfizer Inc. Refractory Multiple Myeloma Product
Table 64. Pfizer Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 65. Pfizer Inc. Recent Development
Table 66. Janssen Global Services, LLC Company Details
Table 67. Janssen Global Services, LLC Business Overview
Table 68. Janssen Global Services, LLC Refractory Multiple Myeloma Product
Table 69. Janssen Global Services, LLC Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 70. Janssen Global Services, LLC Recent Development
Table 71. Gilead Sciences, Inc. Company Details
Table 72. Gilead Sciences, Inc. Business Overview
Table 73. Gilead Sciences, Inc. Refractory Multiple Myeloma Product
Table 74. Gilead Sciences, Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 75. Gilead Sciences, Inc. Recent Development
Table 76. Fresenius Kabi Company Details
Table 77. Fresenius Kabi Business Overview
Table 78. Fresenius Kabi Refractory Multiple Myeloma Product
Table 79. Fresenius Kabi Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 80. Fresenius Kabi Recent Development
Table 81. GSK plc. Company Details
Table 82. GSK plc. Business Overview
Table 83. GSK plc. Refractory Multiple Myeloma Product
Table 84. GSK plc. Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 85. GSK plc. Recent Development
Table 86. Novartis AG Company Details
Table 87. Novartis AG Business Overview
Table 88. Novartis AG Refractory Multiple Myeloma Product
Table 89. Novartis AG Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 90. Novartis AG Recent Development
Table 91. Takeda Pharmaceutical Company Limited Company Details
Table 92. Takeda Pharmaceutical Company Limited Business Overview
Table 93. Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Product
Table 94. Takeda Pharmaceutical Company Limited Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 95. Takeda Pharmaceutical Company Limited Recent Development
Table 96. Genentech, Inc. Company Details
Table 97. Genentech, Inc. Business Overview
Table 98. Genentech, Inc. Refractory Multiple Myeloma Product
Table 99. Genentech, Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 100. Genentech, Inc. Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Refractory Multiple Myeloma Product Picture
Figure 2. Global Refractory Multiple Myeloma Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 3. Global Refractory Multiple Myeloma Market Size 2018-2033 (US$ Million)
Figure 4. United States Refractory Multiple Myeloma Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 5. United States Refractory Multiple Myeloma Market Size 2018-2033 (US$ Million)
Figure 6. United States Refractory Multiple Myeloma Market Share in Global 2018-2033
Figure 7. Refractory Multiple Myeloma Report Years Considered
Figure 8. Product Picture of Proteosome Inhibitor
Figure 9. Product Picture of Immunomodulators
Figure 10. Product Picture of Anti-CD38 Monoclonal Antibody
Figure 11. Product Picture of Others
Figure 12. Global Refractory Multiple Myeloma Market Share by Type in 2022 & 2033
Figure 13. Global Refractory Multiple Myeloma Market Size by Type (2018-2033) & (US$ Million)
Figure 14. Global Refractory Multiple Myeloma Market Share by Type (2018-2033)
Figure 15. United States Refractory Multiple Myeloma Market Share by Type in 2022 & 2033
Figure 16. United States Refractory Multiple Myeloma Market Size by Type (2018-2033) & (US$ Million)
Figure 17. United States Refractory Multiple Myeloma Market Share by Type (2018-2033)
Figure 18. Product Picture of Hospital
Figure 19. Product Picture of Specialty Clinic
Figure 20. Product Picture of Others
Figure 21. Global Refractory Multiple Myeloma Market Share by Application in 2022 & 2033
Figure 22. Global Refractory Multiple Myeloma Market Size by Application (2018-2033) & (US$ Million)
Figure 23. Global Refractory Multiple Myeloma Market Share by Application (2018-2033)
Figure 24. United States Refractory Multiple Myeloma Market Share by Application in 2022 & 2033
Figure 25. United States Refractory Multiple Myeloma Market Size by Application (2018-2033) & (US$ Million)
Figure 26. United States Refractory Multiple Myeloma Market Share by Application (2018-2033)
Figure 27. The Top 5 and 10 Largest Companies of Refractory Multiple Myeloma in the World: Market Share by Refractory Multiple Myeloma Revenue in 2022
Figure 28. Global Refractory Multiple Myeloma Market Size Market Share by Region: 2018 VS 2022 VS 2033
Figure 29. Global Refractory Multiple Myeloma Market Share by Region (2018-2033)
Figure 30. Americas Refractory Multiple Myeloma Market Size Growth Rate 2018-2033 (US$ Million)
Figure 31. Americas Refractory Multiple Myeloma Market Share by Type (2018-2033)
Figure 32. Americas Refractory Multiple Myeloma Market Share by Application (2018-2033)
Figure 33. United States Refractory Multiple Myeloma Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 34. Canada Refractory Multiple Myeloma Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 35. Mexico Refractory Multiple Myeloma Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 36. Brazil Refractory Multiple Myeloma Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 37. EMEA Refractory Multiple Myeloma Market Size Growth Rate 2018-2033 (US$ Million)
Figure 38. EMEA Refractory Multiple Myeloma Market Share by Type (2018-2033)
Figure 39. EMEA Refractory Multiple Myeloma Market Share by Application (2018-2033)
Figure 40. Europe Refractory Multiple Myeloma Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 41. Middle East Refractory Multiple Myeloma Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 42. Africa Refractory Multiple Myeloma Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 43. China Refractory Multiple Myeloma Market Size Growth Rate 2018-2033 (US$ Million)
Figure 44. China Refractory Multiple Myeloma Market Share by Type (2018-2033)
Figure 45. China Refractory Multiple Myeloma Market Share by Application (2018-2033)
Figure 46. APAC Refractory Multiple Myeloma Market Size Growth Rate 2018-2033 (US$ Million)
Figure 47. APAC Refractory Multiple Myeloma Market Share by Type (2018-2033)
Figure 48. APAC Refractory Multiple Myeloma Market Share by Application (2018-2033)
Figure 49. Japan Refractory Multiple Myeloma Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 50. South Korea Refractory Multiple Myeloma Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 51. China Taiwan Refractory Multiple Myeloma Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 52. Southeast Asia Refractory Multiple Myeloma Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 53. India Refractory Multiple Myeloma Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 54. Bristol Myers Squibb Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 55. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 56. Pfizer Inc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 57. Janssen Global Services, LLC Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 58. Gilead Sciences, Inc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 59. Fresenius Kabi Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 60. GSK plc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 61. Novartis AG Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 62. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 63. Genentech, Inc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries